OPC 41061 IN PTS WITH HYPONATREMIA SECONDARY TO LIVER DISEASE

这项研究的目标是找到一条剂量滴定曲线 一种新型加压素II受体拮抗剂在患者中的疗效 继发于肝病的低钠血症。在这项多中心研究中 预计这种新药的剂量为30至60毫克(基于 第一阶段研究)将有效地启动吸纳。这是一个 安慰剂对照、双盲、多中心、多阶段研究 在仔细评估后增加药物剂量的情况 上一次剂量是通过参与者之间的电话会议进行的 调查人员。

The goal of this study is to find a dose titration curve for the effectiveness of a new vasopressin ii receptor antagonists in patients with hyponatremia secondary to liver disease. In this multicenter study it is expected that 30 to 60 mg dose of this new medication (based on the phase i study) will be effective in initiating adqueresis. This is a placebo controlled, double blinded, multicenter study with several phases where dose of the medication is increased after a careful evaluation of the previous dose by a conference call among the participating investigators.